FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4301398575> ?p ?o ?g. }

• W4301398575 endingPage "45.e8" @default.
• W4301398575 startingPage "45.e1" @default.
• W4301398575 abstract "Although transplant-associated thrombotic microangiopathy (TA-TMA) commonly complicates pediatric hematopoietic cellular therapy (HCT), pulmonary manifestations and histology of TA-TMA (pTA-TMA) are rarely reported, with scant data available on timing, risk factors, pathogenesis, and outcomes. Pulmonary hypertension (PH) and diffuse alveolar hemorrhage (DAH) are recognized manifestations of pTA-TMA. The objective of this study was to characterize the pathologic findings, outcomes, and coincident diagnoses preceding biopsy-proven pTA-TMA. In Institutional Review Board- approved retrospective studies, available lung tissue was reviewed at 2 institutions between January 2016 and August 2021 to include those with pulmonary vascular pathology. Histologic features of pTA-TMA were present in 10 children with prior respiratory decline after an allogeneic HCT (allo-HCT; n = 9) or autologous HCT (n = 1). Pathologic lesions included muscular medialization, microthrombi, and red cell fragments, in addition to perivasculitis and intimal arteritis. Parenchymal findings included diffuse alveolar damage, organizing pneumonia, and plasmocytic infiltrates. Six children were clinically diagnosed with TA-TMA, and all were treated with eculizumab, at a median of 2.5 days after clinical diagnosis (range, 0 to 11 days). Four were identified postmortem. Coincident pulmonary infection was confirmed in 8 of the 10 patients. Five allo-HCT recipients (56%) experienced graft-versus-host disease (GVHD; 4 acute, 1 chronic) prior to the onset of respiratory symptoms. Two patients (20%) had clinically recognized DAH, although 9 (90%) had evidence of DAH on histology. Although all 10 patients underwent echocardiography at the time of symptom onset and 9 had serial echocardiograms, only 2 patients had PH detected. Treatments varied and included sildenafil (n = 3), steroids (n = 1), and eculizumab (n = 6). One patient was alive at the time of this report; the remaining 9 died, at a median of 52 days after onset of respiratory symptoms (range 4 to 440 days) and a median of 126 days post-HCT (range, 13 to 947 days). pTA-TMA is a heterogeneous histologic disease characterized by arteriolar inflammation, microthrombi, and often DAH. pTA-TMA presented with respiratory decline with systemic TA-TMA in all patients. Clinicians should maintain a high degree of suspicion for DAH in patients with TA-TMA and pulmonary symptoms. Coincident rates of GVHD and pulmonary infections were high, whereas the rate of PH identified by echocardiography was 20%. Outcomes were poor despite early use of eculizumab and other therapies. Our data merit consideration of pTA-TMA in patients with acute respiratory decline in the setting of systemic TA-TMA, GVHD, and infection. Investigation of additional therapies for pTA-TMA is needed as well. © 2022 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc." @default.
• W4301398575 created "2022-10-05" @default.
• W4301398575 creator A5003061271 @default.
• W4301398575 creator A5009628155 @default.
• W4301398575 creator A5012627913 @default.
• W4301398575 creator A5020867146 @default.
• W4301398575 creator A5032783951 @default.
• W4301398575 creator A5033133009 @default.
• W4301398575 creator A5036788225 @default.
• W4301398575 creator A5040273932 @default.
• W4301398575 creator A5046576538 @default.
• W4301398575 creator A5046929879 @default.
• W4301398575 creator A5063350418 @default.
• W4301398575 creator A5078204460 @default.
• W4301398575 creator A5089080530 @default.
• W4301398575 date "2023-01-01" @default.
• W4301398575 modified "2023-09-27" @default.
• W4301398575 title "Pulmonary Manifestations and Vascular Changes in Pediatric Transplantation-Associated Thrombotic Microangiopathy" @default.
• W4301398575 cites W1873906687 @default.
• W4301398575 cites W1993215990 @default.
• W4301398575 cites W2002800188 @default.
• W4301398575 cites W2005580535 @default.
• W4301398575 cites W2010846142 @default.
• W4301398575 cites W2011896694 @default.
• W4301398575 cites W2020753889 @default.
• W4301398575 cites W2049146476 @default.
• W4301398575 cites W2085644837 @default.
• W4301398575 cites W2092646091 @default.
• W4301398575 cites W2092652294 @default.
• W4301398575 cites W2096665768 @default.
• W4301398575 cites W2098196669 @default.
• W4301398575 cites W2114930069 @default.
• W4301398575 cites W2123753762 @default.
• W4301398575 cites W2132611166 @default.
• W4301398575 cites W2138062831 @default.
• W4301398575 cites W2269614825 @default.
• W4301398575 cites W2379365975 @default.
• W4301398575 cites W2553923194 @default.
• W4301398575 cites W2743895474 @default.
• W4301398575 cites W2759257825 @default.
• W4301398575 cites W2792985650 @default.
• W4301398575 cites W2798240688 @default.
• W4301398575 cites W2887339279 @default.
• W4301398575 cites W2897515101 @default.
• W4301398575 cites W2898432878 @default.
• W4301398575 cites W2908566839 @default.
• W4301398575 cites W2967174380 @default.
• W4301398575 cites W2972134324 @default.
• W4301398575 cites W3017245290 @default.
• W4301398575 cites W3033416765 @default.
• W4301398575 cites W3093233637 @default.
• W4301398575 cites W3113832250 @default.
• W4301398575 cites W3126012658 @default.
• W4301398575 cites W4200073413 @default.
• W4301398575 cites W4221011551 @default.
• W4301398575 cites W4295078871 @default.
• W4301398575 doi "https://doi.org/10.1016/j.jtct.2022.09.026" @default.
• W4301398575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36202334" @default.
• W4301398575 hasPublicationYear "2023" @default.
• W4301398575 type Work @default.
• W4301398575 citedByCount "2" @default.
• W4301398575 countsByYear W43013985752023 @default.
• W4301398575 crossrefType "journal-article" @default.
• W4301398575 hasAuthorship W4301398575A5003061271 @default.
• W4301398575 hasAuthorship W4301398575A5009628155 @default.
• W4301398575 hasAuthorship W4301398575A5012627913 @default.
• W4301398575 hasAuthorship W4301398575A5020867146 @default.
• W4301398575 hasAuthorship W4301398575A5032783951 @default.
• W4301398575 hasAuthorship W4301398575A5033133009 @default.
• W4301398575 hasAuthorship W4301398575A5036788225 @default.
• W4301398575 hasAuthorship W4301398575A5040273932 @default.
• W4301398575 hasAuthorship W4301398575A5046576538 @default.
• W4301398575 hasAuthorship W4301398575A5046929879 @default.
• W4301398575 hasAuthorship W4301398575A5063350418 @default.
• W4301398575 hasAuthorship W4301398575A5078204460 @default.
• W4301398575 hasAuthorship W4301398575A5089080530 @default.
• W4301398575 hasConcept C126322002 @default.
• W4301398575 hasConcept C134018914 @default.
• W4301398575 hasConcept C142724271 @default.
• W4301398575 hasConcept C2776513394 @default.
• W4301398575 hasConcept C2777714996 @default.
• W4301398575 hasConcept C2777878052 @default.
• W4301398575 hasConcept C2779134260 @default.
• W4301398575 hasConcept C2780930700 @default.
• W4301398575 hasConcept C2910574342 @default.
• W4301398575 hasConcept C2911091166 @default.
• W4301398575 hasConcept C555293320 @default.
• W4301398575 hasConcept C57742111 @default.
• W4301398575 hasConcept C71924100 @default.
• W4301398575 hasConceptScore W4301398575C126322002 @default.
• W4301398575 hasConceptScore W4301398575C134018914 @default.
• W4301398575 hasConceptScore W4301398575C142724271 @default.
• W4301398575 hasConceptScore W4301398575C2776513394 @default.
• W4301398575 hasConceptScore W4301398575C2777714996 @default.
• W4301398575 hasConceptScore W4301398575C2777878052 @default.
• W4301398575 hasConceptScore W4301398575C2779134260 @default.
• W4301398575 hasConceptScore W4301398575C2780930700 @default.
• W4301398575 hasConceptScore W4301398575C2910574342 @default.

• next